Endocyte Bullish on Potential Blockbuster

Posted: Updated:
(image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded. (image courtesy of Endocyte) Mike Sherman previously served as chief financial officer and helped the company transition to being publicly-traded.
WEST LAFAYETTE -

The chief executive officer of West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is using a word to describe the company's $12 million worldwide licensing acquisition of a late-stage prostate cancer therapy that he says is often overused: transformational. "In this case, the word is absolutely fitting," said Mike Sherman during a conference call with investors detailing the deal with Germany-based ABX GmbH. Endocyte has been working to reverse a series of quarterly losses in recent years, including a major restructuring and work force reduction announced in June.

Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020. "Our experience with PSMA targeting and companion imaging development, in addition to our relationships with distinguished prostate cancer investigators from around the world, uniquely position Endocyte to lead this therapy to registration," Sherman said in a statement. During Monday's conference call, he added the therapy, if it meets approvals, would position Endocyte in a leading position in a $1 billion prostate cancer-fighting market.

Sherman and Chief Medical Officer Alison Armour say the high potential of the prostate-specific membrane antigen presents a rare opportunity. "Despite advances in the last decade that slow the progression of prostate cancer, once metastasized it is nearly always lethal, leading to 300,000 worldwide deaths annually," said Armour. "177Lu-PSMA-617 has demonstrated the most compelling activity of any drug currently in development for these post-chemotherapy patients."

Aside from a "very targeted" proof-of-concept data effort for the company's CAR T-cell program, Sherman says Endocyte's resources will be focused on developing the promising prostate cancer therapy. Additionally, "we will explore out-licensing opportunities for all other development programs," he said.

Down the line, Sherman says Endocyte has an opportunity to develop a pipeline of similar therapies that target other deadly diseases. He has served in c-level roles with the company for the last 11 years and in mid-2016, succeeded co-founder Ron Ellis as president and CEO.

Mike Sherman has an ambitious timeline for PSMA-617, which he says could begin the clinical trial process early next year and complete trial stages as early as 2020.
  • Perspectives

    • Do You Make These Top 5 Marketing Mistakes?

      Picture this: You’re the CEO of a multi-million dollar company. In just a few short years, you have led your firm in quickly become a rising star within your industry. Now, you’re ready to make your entrance into the big leagues known at this year’s premier tradeshow. The only problem is that your rapid growth has outpaced your "DIY" marketing. And to be taken seriously at the next level, your company needs a strong marketing message that clearly...

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • French Lick Resort Details $17M Expansion

      French Lick Resort has announced plans for a $17 million expansion project. The Orange County venue says construction has already begun on a six-story guestroom addition and new sports bar, which is expected to be complete in the fall of 2019. The project will add 56 guestrooms to French Lick, bringing the total number of rooms to 742 between the resort's two hotels. Both parts of the project, which will total more than 54,000 square feet, are being built near French Lick Casino.

    • Thor Set to Become Largest RV Maker in The World

      Elkhart-based Thor Industries Inc. (NYSE: THO) has announced an agreement to acquire a German recreational vehicle manufacturer for approximately $2.4 billion. Once complete, Thor says the deal for Erwin Hymer Group SE will create the world's largest RV maker. EHG currently employs more than 7,300 globally and its RVs are sold through a network of over 1,200 retailers. The companies say they expect no change in employee headcount or number of facilities as a result of...

    • (Image courtesy of AM General)

      AM General Wins $560M Humvee Contract

      A major contract has been awarded to South Bend-based AM General LLC. The more than $560 million deal involves production of 2,800 Humvee ambulances. The first vehicles, AM General says, are expected to be delivered in the second quarter of next year. U.S. Army Contracting Command in Warren, Michigan is the contracting activity. AM General is partnering with Rock Island Arsenal Executive Vice President of U.S. Defense Chris Vanslager says...

    • Mike Strohl served as vice chairman for 2017-2018. (photo courtesy of the 500 Festival)

      500 Festival Names Board Officers

      The Indianapolis-based 500 Festival has elected officers for its 2018-2019 board of directors. The nonprofit says Mike Strohl, chief customer officer for Citizens Energy Group, will serve as chairman of the board. Strohl previously served as vice chairman of the board for the 500 Festival. 

    • Sigstr Locks Down $4M in Funding

      The head of an Indianapolis marketing tech company that has secured another multi-million dollar round of funding says there are multiple benefits to its location in the Hoosier State. Email signature and relationship marketing platform Sigstr has landed $4 million from investors led by New Jersey-based Edison Partners. Chief Executive Officer Bryan Wade attributes Sigstr's rapid upward trajectory to factors including...